Poor
Not Aligned
Patient Risk:
Moderate
Summary
Claims about clinical use and cardiovascular risk reduction are partially supported by the provided label sections, but numerous non-label cost/access/discount and other promotional statements are not supported and should be excluded when adhering to FDA labeling.
Category Scores
Accurate Statements
Vascepa is a prescription medication containing the omega-3 fatty acid EPA.
12 Clinical Pharmacology (Mechanism of Action) mentions EPA.
Vascepa reduces the risk of heart attack and stroke.
1 INDICATIONS AND USAGE and 14 Clinical Studies (Prevention of Cardiovascular Events) describe reduction in myocardial infarction and stroke risk.
Vascepa works by reducing triglyceride levels.
1 INDICATIONS AND USAGE (reduce TG levels) and 12 Clinical Pharmacology (Mechanism of Action) describe TG reduction mechanisms.
Reducing triglyceride levels can reduce the risk of cardiovascular events.
1 INDICATIONS AND USAGE and 14 Clinical Studies support cardiovascular event risk reduction in patients with elevated triglycerides, though the label does not explicitly claim a causal mechanism framed as TG reduction driving the event reduction.
Unsupported Statements
Reducing triglyceride levels can help to prevent the formation of blood clots.
Not supported by the provided label sections.
The cost of Vascepa can vary depending on a patient's insurance coverage, the pharmacy, and the dosage.
Pricing/coverage statements are not supported by the provided label sections.
The average cost of Vascepa in the United States is around $1,500 per month for a 30-day supply.
Specific numeric cost is not supported by the provided label sections.
There is no specific Vascepa insurance discount program.
Not supported by the provided label sections.
Many pharmaceutical companies, including the manufacturer of Vascepa, offer patient assistance programs (PAPs).
Not supported by the provided label sections.
Patient assistance programs typically have income and eligibility requirements.
Not supported by the provided label sections.
Manufacturer of Vascepa may offer coupons or rebates to help patients save on the medication.
Not supported by the provided label sections.
Some pharmacies offer discount programs that can help patients save on Vascepa.
Not supported by the provided label sections.
Patients eligible for government assistance programs such as Medicaid or the Veterans Administration may be able to access Vascepa at a reduced cost.
Not supported by the provided label sections.
The manufacturer can be contacted to inquire about available patient assistance programs or coupons.
Not supported by the provided label sections.
Patients can ask their pharmacist about available discount programs or coupons.
Not supported by the provided label sections.
Patients can ask their insurance provider about available discounts or programs that can help them save on Vascepa.
Not supported by the provided label sections.
Patients can apply for government assistance programs if eligible to access Vascepa at a reduced cost.
Not supported by the provided label sections.
Vascepa is described as a highly effective medication for reducing triglycerides.
The provided label sections do not support the descriptor 'highly effective.'
Vascepa is described as having cost as a significant barrier for many patients.
Not supported by the provided label sections.
Vascepa can be reduced in cost by exploring patient assistance programs, manufacturer coupons, and pharmacy discount programs.
Not supported by the provided label sections.
Vascepa is typically covered by most insurance plans.
Not supported by the provided label sections.
Cost-sharing requirements for Vascepa may vary.
Not supported by the provided label sections.
Patients with a high deductible plan may be eligible for a Vascepa insurance discount.
Not supported by the provided label sections.
The manufacturer of Vascepa offers a patient assistance program that can help eligible patients access the medication at a reduced cost.
Not supported by the provided label sections.
A manufacturer coupon can be used in conjunction with insurance coverage to reduce the cost of Vascepa.
Not supported by the provided label sections.
Patients who are eligible for government assistance programs, such as Medicaid or the Veterans Administration, may be able to access Vascepa at a reduced cost.
Not supported by the provided label sections.
Contradictions
Important Omissions
The response set did not address FDA-label dosing/administration, contraindications, boxed warnings, warnings/precautions, drug interactions, or specific populations (e.g., pregnancy, pediatrics), which are material components of prescribing information when evaluating label adherence for safety.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Non-label cost/access statements are unlikely to directly affect pharmacologic safety, but inclusion of unsupported claims and lack of label-required safety sections prevents a complete label-adherence assessment.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Not Aligned
Primary Issue
Multiple unsupported non-label claims (cost, discounts, patient assistance, pharmacy/insurance coverage) and one unsupported clinical mechanism framing (blood clots) are included.
Suggested Improvement
Remove all cost/access/discount/PAP/coupon/coverage statements not present in the FDA-approved labeling; restrict clinical claims to the specific labeled indications and labeled cardiovascular risk reduction endpoints described in the provided sections.